With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy
LEARN MORE

The first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample and independent of a positive blood culture.

T2Candida Case Study
Secondary Candidemia in Critically Ill COVID-19 Patient
READ CASE STUDY

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Enhancing the standard of care.

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2 technology

hospital_icon
Gregorio Marañón Hospital in Madrid, Spain
Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain.
hospital_icon
Rigshospitalet, Denmark
"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis."
hospital_icon
Gemelli Hospital, Italy
66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria
hospital_icon
La Paz Hospital University, Spain
T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient.

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

Improve Outcomes more bold-01
∼50 million
cases per year
Worldwide Deaths
11 million
deaths annually, worldwide.
1 in 3
1 in 5
deaths worldwide
Integrate T2 Biosystems Panels into your hospital today!